gsk201504136k4.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 


GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 13 April 2015, of changes in the interests of the following Persons Discharging Managerial Responsibility, following increases in their notional interests in Ordinary Shares, at a price of 1606.50 pence per Share, on the re-investment of dividends paid on Ordinary Shares held in the GlaxoSmithKline Deferred Investment Award Programme.
 
 
 
Director/PDMR
 
 
  Ordinary Shares
 
Mr R G Connor
 
  411.017
 
Mr S A Hussain
 
  513.771
 
Mr D S Redfern
 
  411.017
 
Ms C Thomas
 
  411.017
 
Dr P J T Vallance
 
  513.771
 
Ms E Walmsley
 
  941.862
 
Mrs V A Whyte
 
  115.049
 
 
V A Whyte
Company Secretary
 
13 April 2015
 
 


 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 13, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc